Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- AbbVie to File for Dual Hep C Treatments Offering Shorter Treatment Time than Harvoni, Sovaldi
November 18, 2016
- Sanofi Begins Praluent Post-Marketing Study in Japanese ACS Patients
November 17, 2016
- Sanofi Japan Looks to Launch 20-Plus Products by 2020: New Chief
November 17, 2016
- Ono Braces for “Unexpected Negative Impact” from Price Cut, Calls for Stable Rules
November 17, 2016
- Japan CNS Market to Reach 648.7 Billion Yen in 2024: Fuji Keizai
November 17, 2016
- First DOAC Antidote to Hit Japan Market This Month
November 16, 2016
- Nipro Pharma Forms Capital Tie-Up with Vietnam’s Mekophar
November 16, 2016
- Sawai Might See Teva-Takeda JV Impact on Distribution Channel: President
November 15, 2016
- Ethical Drug Sales Down 5.6% in September: Crecon Report
November 15, 2016
- Pace of Generic Substitution Slowing at Pharmacies: Sawai President
November 15, 2016
- Regenerative Medicine Market to Expand to 142.1 Billion Yen in 2030: Fuji Keizai
November 11, 2016
- Opdivo Significantly Prolongs OS in Gastric Cancer Patients in PIII Study: Ono
November 11, 2016
- Takecab Most Promoted Drug in September: Anterio
November 11, 2016
- Top 4 Wholesalers See Lower Sales in April-September If Hep C Meds Excluded
November 11, 2016
- Enrollment Completed for PIII Adcetris Study for Mature T-Cell Lymphoma: Takeda
November 10, 2016
- Nippon Shinyaku’s DMD Med Gets Fast Track Status in US
November 10, 2016
- Kipres Generics Earn Bronchial Asthma Indication in Droves
November 10, 2016
- MSD to Seek Keytruda Listing after Adding Lung Cancer Indication
November 10, 2016
- Takeda to Collaborate with 2 Universities on Application of Miniature Liver Technology to Drug Discovery Research
November 10, 2016
- Kipres AG’s Market Penetration Faster than Expected: Kyorin President
November 9, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…